Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review

Abstract Background The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immu...

Descripción completa

Detalles Bibliográficos

Autores principales:	Chiaki Imai, Masashi Uchida, Koji Takahashi, Izumi Ohno, Yuichi Takiguchi, Itsuko Ishii
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2026-03-01
Colección:	Journal of Pharmaceutical Health Care and Sciences
Materias:	Pituitary apoplexy Immune checkpoint inhibitors Ipilimumab Nivolumab Adverse events Melanoma
Acceso en línea:	https://doi.org/10.1186/s40780-026-00564-4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!